Lipigon Pharmaceuticals AB (publ) (STO:LPGO)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0076
+0.0012 (18.75%)
Mar 9, 2026, 5:01 PM CET
-94.57%
Market Cap 4.61M
Revenue (ttm) 1.32M
Net Income (ttm) -35.97M
Shares Out 605.93M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,651,632
Average Volume 7,027,547
Open 0.0064
Previous Close 0.0064
Day's Range 0.0064 - 0.0110
52-Week Range 0.0040 - 0.3695
Beta 0.59
RSI 45.15
Earnings Date Feb 20, 2026

About STO:LPGO

Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia. The company has a license agreement with Leader... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol LPGO
Full Company Profile

Financial Performance

In 2024, STO:LPGO's revenue was 10.29 million, a decrease of -37.30% compared to the previous year's 16.41 million. Losses were -25.26 million, 108.3% more than in 2023.

Financial Statements

News

There is no news available yet.